87 filings
8-K
ITRM
Iterum Therapeutics plc
14 Aug 24
Iterum Therapeutics Reports Second Quarter 2024 Financial Results
7:15am
8-K
ITRM
Iterum Therapeutics plc
6 Aug 24
Iterum Therapeutics Announces Expiration and Results of Rights Offering
5:25pm
8-K
ITRM
Iterum Therapeutics plc
22 Jul 24
Iterum Therapeutics Commences Rights Offering
8:30am
8-K
ITRM
Iterum Therapeutics plc
26 Jun 24
Other Events
5:24pm
8-K
ITRM
Iterum Therapeutics plc
21 Jun 24
Submission of Matters to a Vote of Security Holders
8:30am
8-K
vcwupwj 9lyjit
31 May 24
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
8:30am
8-K
45f6 ddlwv8sn1gxvu
13 May 24
Iterum Therapeutics Reports First Quarter 2024 Financial Results
7:15am
8-K
8p5oeoy4f zlsegfys4
10 May 24
Departure of Directors or Certain Officers
4:15pm
8-K
cd7hvj9
29 Apr 24
Other Events
4:30pm
8-K
svm5xp92llgsxn
5 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
sdqzj2h jrfnicl4v5
29 Mar 24
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
7:15am
8-K
cqa6bc6bt3 opr7e7nb
6 Mar 24
Iterum Therapeutics Provides Business Update
8:16am
8-K
n79blunmhdzot0
30 Jan 24
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
troid u1otedam2
30 Jan 24
Regulation FD Disclosure
7:15am
8-K
smvfzx
29 Dec 23
Departure of Directors or Certain Officers
4:30pm
8-K
83iieiaiar5g72wj6
4 Dec 23
Other Events
8:30am
8-K
dgvhfrzci6jp4a9s
14 Nov 23
Iterum Therapeutics Reports Third Quarter 2023 Financial Results
12:00am
8-K
u66atp g9iwlkq
24 Oct 23
Other Events
9:00am
8-K
i9847z6pmbas8
29 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:00pm
8-K
1x8mgetg7nq3fun99
11 Aug 23
Iterum Therapeutics Reports Second Quarter 2023 Financial Results
7:15am